J. Custers

发表

Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field.

R. Alemany, N. Chandra, A. Rajan, 2014, Human gene therapy.

Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice.

V. A. Stewart, M. Demoitié, Joe D. Cohen, 2008, Vaccine.

Priming with an Adenovirus 35-Circumsporozoite Protein (CS) Vaccine followed by RTS,S/AS01B Boosting Significantly Improves Immunogenicity to Plasmodium falciparum CS Compared to That with Either Malaria Vaccine Alone

V. A. Stewart, M. Demoitié, Joe D. Cohen, 2007, Infection and Immunity.

Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics.

M. Havenga, R. Vogels, W. Barclay, 2009, Vaccine.

Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein1

B. Walker, M. Addo, M. Lifton, 2005, The Journal of Immunology.

Protein Primarily against the Adenovirus Hexon Serotype 5 Vaccine Vectors Are Directed Neutralizing Antibodies to Adenovirus

Jaap, B. Walker, M. Addo, 2005 .

Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity1

S. Kostense, M. Lifton, N. Letvin, 2004, The Journal of Immunology.

Pre-Existing Anti-Ad5 Immunity Serotype 35 Vaccine in the Presence of Immunogenicity of Recombinant Adenovirus

Jaap, Newberg, S. Kostense, 2004 .

Human Adenovirus Type 26 Infection Mediated by αvβ3 Integrin Is Caveolin-1-Dependent

D. Majhen, J. Custers, D. Nestić, 2022, Microbiology spectrum.

Brunenders: a partially attenuated historic poliovirus type I vaccine strain.

Y. Liu, E. Wimmer, H. Schuitemaker, 2015, The Journal of general virology.

Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses.

H. Schuitemaker, M. Kikkert, R. Vogels, 2020, NPJ vaccines.

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment

Robert T. Chen, Roy G van Heesbeen, H. Schuitemaker, 2020, Vaccine.

T-DNA tagging in Brassica napus as an efficient tool for the isolation of new promoters for selectable marker genes

J. Custers, A. Ponstein, S. Hoekstra, 2003, Plant Molecular Biology.

Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge

Joshua C. Johnson, R. Koup, N. Sullivan, 2011, Journal of Virology.

Novel Replication-Incompetent Vector Derived from Adenovirus Type 11 (Ad11) for Vaccination and Gene Therapy: Low Seroprevalence and Non-Cross-Reactivity with Ad5

B. Berkhout, P. Quax, M. Havenga, 2004, Journal of Virology.

Development of a replication‐deficient adenoviral vector‐based vaccine candidate for the interception of HPV16‐ and HPV18‐induced infections and disease

E. Bunnik, H. Schuitemaker, K. Oosterhuis, 2017, International journal of cancer.

αvβ3 Integrin Is Required for Efficient Infection of Epithelial Cells with Human Adenovirus Type 26

Taco G. Uil, D. Majhen, J. Custers, 2018, Journal of Virology.

Explorer v 3 Integrin is Required for Efficient Infection of Epithelial Cells with Human 1 Adenovirus Type 26

Taco G. Uil, Baker, D. Majhen, 2018 .

Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery.

A. Parker, S. Nicklin, J. Custers, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern

H. Schuitemaker, N. Guimerà, M. Navis, 2021, bioRxiv.

Immunogenicity of an Ad26-based SARS-CoV-2 Omicron Vaccine in Naïve Mice and SARS-CoV-2 Spike Pre-immune Hamsters

H. Schuitemaker, A. Gil, F. Wegmann, 2022, bioRxiv.

Manipulating Adenovirus Hexon Hypervariable Loops Dictates Immune Neutralisation and Coagulation Factor X-dependent Cell Interaction In Vitro and In Vivo

Taco G. Uil, S. Nicklin, J. Custers, 2015, PLoS pathogens.

Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques

D. Lauffenburger, H. Schuitemaker, R. Baric, 2020, Nature.

Isolation and characterisation of a class of carbohydrate oxidases from higher plants, with a role in active defence.

J. Custers, M. Sela-Buurlage, L. Melchers, 2004, The Plant journal : for cell and molecular biology.

Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses.

H. Schuitemaker, K. Oosterhuis, Taco G. Uil, 2018, Vaccine.

Engineering disease resistance in plants

Maarten H. Stuiver, Jerome H. H. V. Custers, J. Custers, 2001, Nature.

A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates

H. Schuitemaker, J. Custers, C. Mire, 2018, PloS one.

Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys.

S. Santra, N. Letvin, J. Custers, 2009, Vaccine.

Challenges in manufacturing adenoviral vectors for global vaccine product deployment.

M. Havenga, A. Lemckert, A. Lipiec, 2014, Human gene therapy.

Cold-Adapted Viral Attenuation (CAVA): Highly Temperature Sensitive Polioviruses as Novel Vaccine Strains for a Next Generation Inactivated Poliovirus Vaccine

E. Wimmer, H. Schuitemaker, J. Cello, 2016, PLoS pathogens.

Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer

C. Napoli, D. Bhella, N. Rooijen, 2008, Cell.

Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters

D. Lauffenburger, H. Schuitemaker, G. Alter, 2020, Nature medicine.

TransferAdenovirus Serotype 5 Gene Effect of Neutralizing Sera on Factor

M. Havenga, J. Custers, J. Goudsmit, 2014 .

Effect of Neutralizing Sera on Factor X-Mediated Adenovirus Serotype 5 Gene Transfer

N. Van Rooijen, M. Havenga, A. Parker, 2008, Journal of Virology.

An alternative to the adenovirus inverted terminal repeat sequence increases the viral genome replication rate and provides a selective advantage in vitro.

Mark Vermeulen, J. Custers, M. Pau, 2014, The Journal of general virology.

Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

H. Schuitemaker, M. Kikkert, R. Vogels, 2020, npj Vaccines.

Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species

H. Schuitemaker, G. Weverling, J. Custers, 2012, PloS one.

Vector Choice Determines Immunogenicity and Potency of Genetic Vaccines against Angola Marburg Virus in Nonhuman Primates

R. Koup, N. Sullivan, P. Jahrling, 2010, Journal of Virology.

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

H. Schuitemaker, M. Robb, P. Goepfert, 2022, The New England journal of medicine.

Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.

H. Schuitemaker, J. Custers, K. Radošević, 2015, Vaccine.

Competing Interests: GJN:

R. Koup, N. Sullivan, P. Jahrling, 2022 .

PER.C6(®) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine.

H. Schuitemaker, V. Klaren, J. Custers, 2013, Vaccine.

Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer.

D. Bhella, N. Van Rooijen, A. Parker, 2009, Blood.

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

D. Lauffenburger, H. Schuitemaker, R. Baric, 2020, Nature.

Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP

H. Schuitemaker, M. Kikkert, Boerries Brandenburg, 2021, The Journal of experimental medicine.

Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV.

E. Wimmer, H. Schuitemaker, J. Cello, 2015, Vaccine.

Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

H. Schuitemaker, M. Kikkert, R. Vogels, 2020, NPJ vaccines.

Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2

H. Schuitemaker, A. Gil, F. Wegmann, 2023, npj Vaccines.

Generation and characterization of a novel candidate gene therapy and vaccination vector based on human species D adenovirus type 56.

N. Chandra, M. Havenga, A. Lemckert, 2018, The Journal of general virology.

Adenoviral Type 35 and 26 Vectors with a Bidirectional Expression Cassette in the E1 Region Show an Improved Genetic Stability Profile and Potent Transgene-Specific Immune Response.

H. Schuitemaker, Mark Vermeulen, J. Custers, 2017, Human gene therapy.

Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates

S. Santra, M. Lifton, N. Letvin, 2012, Vaccine.

Publisher Correction: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

D. Lauffenburger, H. Schuitemaker, R. Baric, 2021, Nature.

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

A. Borobia, H. Schuitemaker, Andrew Gibson, 2022, The Lancet Infectious Diseases.

T-DNA tagging of a pathogen inducible promoter in Arabidopsis thaliana.

J. Custers, L. Melchers, H. Tigelaar, 2002, Molecular plant pathology.

Human AdV-20-42-42, a Promising Novel Adenoviral Vector for Gene Therapy and Vaccine Product Development

M. Havenga, A. Lemckert, H. M. van der Schaar, 2021, bioRxiv.

Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform

H. Schuitemaker, J. Custers, H. Kuipers, 2017, PloS one.

A replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6 cells.

A. D. De Groot, G. Weverling, M. Havenga, 2007, Vaccine.

Synthetic virus seeds for improved vaccine safety: Genetic reconstruction of poliovirus seeds for a PER.C6 cell based inactivated poliovirus vaccine.

H. Schuitemaker, J. Custers, D. Edo-Matas, 2015, Vaccine.

Human Adenovirus Type 26 Induced IL-6 Gene Expression in an αvβ3 Integrin- and NF-κB-Dependent Manner

D. Majhen, J. Custers, J. Knežević, 2022, Viruses.

Pseudotyping Serotype 5 Adenovirus with the Fiber from Other Serotypes Uncovers a Key Role of the Fiber Protein in Adenovirus 5-Induced Thrombocytopenia.

S. Hemmi, J. Custers, F. Vigant, 2016, Human gene therapy.

Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction

J. Custers, S. Waddington, K. White, 2013, Gene Therapy.

Recombinant measles virus incorporating heterologous viral membrane proteins for use as vaccines.

J. Custers, K. Radošević, P. Wanningen, 2016, The Journal of general virology.

Immune Protection of Nonhuman Primates against Ebola Virus with Single Low-Dose Adenovirus Vectors Encoding Modified GPs

R. Koup, N. Sullivan, P. Jahrling, 2006, PLoS medicine.